Can Eledon Pharmaceuticals’ (ELDN) Mixed Kidney Trial Results Reshape Its Competitive Edge in Transplant Care?

• In November 2025, Eledon Pharmaceuticals presented results from its Phase 2 BESTOW trial of tegoprubart for the prevention of organ rejection in kidney transplant recipients at the American Society of Nephrology's Kidney Week Annual Meeting.
• Although the primary endpoint did not meet statistical significance, the drug showed a promising safety profile and higher kidney function in some key patient subgroups compared to standard tacrolimus therapy.
• We'll explore how tegoprubart's differentiated safety and kidney function results could influence Eledon Pharmaceuticals' longer-term investment case.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

What Is Eledon Pharmaceuticals' Investment Narrative?

To be a shareholder in Eledon Pharmaceuticals right now, you need conviction in its ability to turn promising clinical results into regulatory approvals and, eventually, commercial success. The new Phase 2 BESTOW trial data for tegoprubart is an important update: while not a home run in terms of primary efficacy endpoint, it does reinforce the drug’s safety and a potential benefit for specific patient subgroups over tacrolimus. This has shifted some attention from pure efficacy to the differentiated safety profile, which could become a key near-term catalyst if regulators and partners see value in that distinction for kidney transplant recipients. The trial update is material and could alter short-term sentiment, but it doesn’t resolve the key risk: Eledon still faces an extended path to revenue, given no product is approved yet, and consensus expects earnings to contract. With shares under pressure and no forecast revenue next year, the balance between scientific progress and financial runway remains as precarious as ever.
However, the path to commercial viability is not yet clear, and that’s something investors need to watch.

The analysis detailed in our Eledon Pharmaceuticals valuation report hints at an deflated share price compared to its estimated value.

Exploring Other Perspectives

Simply Wall St Community fair value estimates for Eledon Pharmaceuticals range from US$0.95 to US$9.50 based on three unique opinions. While some see significant upside, ongoing uncertainties around profitability and timelines mean that these views can diverge widely. Consider these diverse outlooks as you weigh if recent trial news changes the risk-reward equation for you.

Explore 3 other fair value estimates on Eledon Pharmaceuticals - why the stock might be worth over 4x more than the current price!

Build Your Own Eledon Pharmaceuticals Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Eledon Pharmaceuticals research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Eledon Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eledon Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com